GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (FRA:41O) » Definitions » Beginning Cash Position

Outlook Therapeutics (FRA:41O) Beginning Cash Position : €5.28 Mil (As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Outlook Therapeutics Beginning Cash Position?

Outlook Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2025 was €5.28 Mil.

Outlook Therapeutics's quarterly Beginning Cash Position declined from Sep. 2024 (€28.86 Mil) to Dec. 2024 (€14.26 Mil) and declined from Dec. 2024 (€14.26 Mil) to Mar. 2025 (€5.28 Mil).

Outlook Therapeutics's annual Beginning Cash Position increased from Sep. 2022 (€14.62 Mil) to Sep. 2023 (€16.30 Mil) and increased from Sep. 2023 (€16.30 Mil) to Sep. 2024 (€21.08 Mil).


Outlook Therapeutics Beginning Cash Position Historical Data

The historical data trend for Outlook Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outlook Therapeutics Beginning Cash Position Chart

Outlook Therapeutics Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.81 10.65 14.62 16.30 21.08

Outlook Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.53 43.88 28.86 14.26 5.28

Outlook Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.


Outlook Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Outlook Therapeutics Business Description

Traded in Other Exchanges
Address
111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Outlook Therapeutics Headlines

No Headlines